Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1ascendis pharmanovo nordiskglp-1obesity

Ascendis regains obesity rights as Novo Nordisk exits monthly GLP-1 deal

Novo Nordisk's withdrawal returns full control of the long-acting GLP-1 program to Ascendis Pharma.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 07:27 ETSource: The Pharma Letter

The wire

  1. 01Novo Nordisk exited its monthly GLP-1 collaboration, returning obesity rights to Ascendis Pharma.
  2. 02Signals Novo prioritizing its internal pipeline as competition in long-acting obesity drugs grows.
  3. 03Ascendis' plans for independent development or repartnering were not stated.

From the source

Ascendis regains obesity rights as Novo exits monthly GLP-1 deal

Read at news.google.com
Source URL https://news.google.com/rss/articles/CBMivgFBVV95cUxQdURETFkzQ0t3ekhSRU8xdjFaVXg5QThXSkdrcWpZaXJZN2tlQm8zOEliQ09FdklnbUdycEZDUG45REU0ZUxrejZGZWVlVUsweE0zZ0hJV3JVcVBLTWdsYmNSSnJONlVaaEsxUDdDSjhJMjRCTXVyV2hRQm5SUTZRaEh1YjRUcWttNGduSl9tTlhTR3dvZ3dkcmFmM21aRWQzdUsyRndlcEJPUFYtazRwTHBOZlloRnFhUDBHTUJB?oc=5